Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is conducting a clinical study titled ‘A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects With Moderate-to-Severe Active Thyroid Eye Disease.’ The study aims to evaluate the safety and effectiveness of AMG 732, a potential treatment for Thyroid Eye Disease (TED), which is significant due to the limited treatment options currently available for this condition.
The intervention being tested is AMG 732, administered as a subcutaneous injection. It is designed to assess safety in healthy participants and efficacy in those with TED, with the goal of providing a new therapeutic option for this challenging condition.
The study follows an interventional design with randomized allocation and a sequential intervention model. It employs double masking, meaning both participants and investigators are unaware of the treatment assignments, to ensure unbiased results. The primary purpose of the study is treatment-focused.
The study began on May 30, 2024, with its primary completion and estimated overall completion dates yet to be announced. The most recent update was submitted on July 25, 2025. These dates are crucial as they indicate the study’s progress and timelines for potential results.
The update on this study could positively influence Amgen’s stock performance and investor sentiment, as successful results may lead to a new product in their portfolio, enhancing their market position. In the competitive landscape, advancements in TED treatment could set Amgen apart from other pharmaceutical companies.
The study is ongoing, with further details available on the ClinicalTrials portal.